Know Cancer

or
forgot password

HER2 Circulating Tumor Cells in Gastric Cancer


N/A
18 Years
N/A
Open (Enrolling)
Both
Gastric Cancer

Thank you

Trial Information

HER2 Circulating Tumor Cells in Gastric Cancer


We propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future
clinical trials incorporating Her-2 targeted agents in gastric cancer. Blood samples will be
collected from metastatic gastric cancer patients.


Inclusion Criteria:



- Patients older than 18 years ② Patients with localized, histologically confirmed
gastric cancer ③ Informed consent form

Exclusion Criteria:

- No informed consent form

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

To survey the frequency of HER2(+) CTC in gastric cancer

Outcome Time Frame:

24month

Safety Issue:

No

Principal Investigator

Won Ki Kang, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Samsung Medical Center

Authority:

Korea: Food and Drug Administration

Study ID:

2009-12-008

NCT ID:

NCT01299688

Start Date:

March 2010

Completion Date:

September 2013

Related Keywords:

  • Gastric Cancer
  • Stomach Neoplasms
  • Neoplastic Cells, Circulating

Name

Location